Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ALL026
MIFTS: 68

Allergic Hypersensitivity Disease

Categories: Immune diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Allergic Hypersensitivity Disease

About this section

MalaCards integrated aliases for Allergic Hypersensitivity Disease:

Name: Allergic Hypersensitivity Disease 12 15
Hypersensitivity 12 77 45 15 74
Allergy 12 56 6 44 17
Allergic Disposition 74
Allergic Condition 74
Allergic Reaction 74
Allergic Disease 12
Allergies 64

Classifications:

MalaCards categories:
Anatomical: Immune diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:1205
MeSH 45 D006967
NCIt 51 C3114
SNOMED-CT 69 21957007 91232002
ICD10 34 T78.4 T78.40
Sources

Summaries for Allergic Hypersensitivity Disease

About this section
MedlinePlus : 44 An allergy is a reaction by your immune system to something that does not bother most other people. People who have allergies often are sensitive to more than one thing. Substances that often cause reactions are Pollen Dust mites Mold spores Pet dander Food Insect stings Medicines Normally, your immune system fights germs. It is your body's defense system. In most allergic reactions, however, it is responding to a false alarm. Genes and the environment probably both play a role. Allergies can cause a variety of symptoms such as a runny nose, sneezing, itching, rashes, swelling, or asthma. Allergies can range from minor to severe. Anaphylaxis is a severe reaction that can be life-threatening. Doctors use skin and blood tests to diagnose allergies. Treatments include medicines, allergy shots, and avoiding the substances that cause the reactions. NIH: National Institute of Allergy and Infectious Diseases

MalaCards based summary : Allergic Hypersensitivity Disease, also known as hypersensitivity, is related to cow milk allergy and beta-lactam allergy, and has symptoms including nausea and vomiting, abdominal pain and pruritus. An important gene associated with Allergic Hypersensitivity Disease is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ertapenem and Alcaftadine have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and lung, and related phenotypes are hematopoietic system and digestive/alimentary

Disease Ontology : 12 An immune system disease that is an exaggerated immune response to allergens, such as insect venom, dust mites, pollen, pet dander, drugs or some foods.

PubMed Health : 64 About allergies: Allergies arise if the body's immune system overreacts to foreign substances (allergens) that are usually harmless in most people, such as pollen or certain foods. The symptoms can vary a lot. In some cases they are quite mild, but they can also be a real nuisance and have a considerable impact in everyday life. Severe allergic reactions may be life-threatening.There are various treatment options for allergies. Some things that trigger allergies (allergens) are easy to avoid, whereas others aren't. Common allergens include the following:

Wikipedia : 77 Hypersensitivity (also called hypersensitivity reaction or intolerance) refers to undesirable reactions... more...

Sources

Related Diseases for Allergic Hypersensitivity Disease

About this section

Diseases related to Allergic Hypersensitivity Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1435)
# Related Disease Score Top Affiliating Genes
1 cow milk allergy 34.2 IL10 IL5 RNASE3
2 beta-lactam allergy 34.1 IL10 IL13 IL4
3 cephalosporin allergy 34.1 IFNG IL10 IL5
4 apple allergy 33.9 CCL17 IL10 IL13 IL4 IL5
5 respiratory allergy 33.6 CCL11 IGHE IL10 IL13 IL4 IL5
6 allergic contact dermatitis 32.8 CCL17 IFNG IL10 IL4 IL5
7 esophagitis, eosinophilic, 1 32.5 CCL11 IL13 IL5
8 blepharoconjunctivitis 32.5 CCL11 IL4 RNASE3
9 giant papillary conjunctivitis 32.5 CCL11 IL4 RNASE3
10 sarcoidosis 1 32.3 CCL17 IFNG IL13 IL9
11 orofacial granulomatosis 32.2 CCL5 CCR3 IFNG IL10 IL4
12 vernal keratoconjunctivitis 32.2 CCL11 CCL5 IL13 IL4 IL5 RNASE3
13 immune system disease 32.1 IFNG IL10 IL4 IL5
14 allergic conjunctivitis 32.0 CCL11 HRH1 IFNG IL13 IL4 IL5
15 autoimmune disease of central nervous system 31.8 CCL5 IFNG IL10 IL4
16 mycobacterium tuberculosis 1 31.5 IFNG IL10 IL4
17 maxillary sinusitis 30.9 CCL5 RNASE3
18 eosinophilic gastroenteritis 30.9 CCL11 EPX IL5 RNASE3
19 gastroenteritis 30.8 CCL11 IL10 IL4 IL5 RNASE3
20 dermatitis 30.8 CCL11 CCL17 IFNG IGHE IL13 IL4
21 ige responsiveness, atopic 30.8 IFNG IGHE IL10 IL13 IL4 IL5
22 inflammatory bowel disease 30.7 IFNG IL10 IL13 IL4
23 tetanus 30.7 IFNG IL10 IL13 IL4 IL5
24 gastrointestinal system disease 30.7 CCL11 IFNG IL10
25 common cold 30.6 CCL11 CCL5 IL13 IL5 RNASE3
26 lung disease 30.6 CCL5 IL10 IL13 IL5 RNASE3
27 leishmaniasis 30.6 IFNG IL10 IL13 IL4 IL5
28 pulmonary fibrosis, idiopathic 30.6 CCL17 CCL5 IFNG IL13
29 food allergy 30.5 CSN1S1 EPX IFNG IL10 IL13 IL4
30 allergic bronchopulmonary aspergillosis 30.5 CCL17 EPX IL4 IL5
31 pollen allergy 30.5 EPX IL13 IL5 RNASE3
32 yellow fever 30.5 CCL5 IL4 IL5
33 aspergillosis 30.5 CCL17 IFNG IL10 IL4 IL5
34 paracoccidioidomycosis 30.5 IFNG IL10 IL4 IL5
35 brucellosis 30.5 IFNG IL10 IL4
36 pneumonia 30.4 CCL11 CCL5 IL10 IL13 IL5
37 cytokine deficiency 30.4 IL13 IL5 IL9
38 egg allergy 30.4 IGHE IL4 IL5
39 chlamydia 30.4 IFNG IL10 IL4
40 q fever 30.3 IFNG IL10 IL4
41 toxic shock syndrome 30.3 IFNG IL10 IL4
42 esophagitis 30.3 CCL11 CCR3 IL13 IL5
43 cutaneous leishmaniasis 30.3 FCER2 IFNG IL10 IL13 IL4 IL5
44 parasitic helminthiasis infectious disease 30.3 IL10 IL13 IL4 IL5 RNASE3
45 genital herpes 30.3 CCL5 IL10 IL4
46 hyper ige syndrome 30.3 IFNG IGHE IL4
47 eales disease 30.3 IFNG IL10 IL4
48 coccidiosis 30.3 IFNG IL10 IL4
49 neuritis 30.3 CCL5 IFNG IL4
50 papillary conjunctivitis 30.2 CCL11 IL4

Graphical network of the top 20 diseases related to Allergic Hypersensitivity Disease:



Diseases related to Allergic Hypersensitivity Disease
Sources

Symptoms & Phenotypes for Allergic Hypersensitivity Disease

About this section

UMLS symptoms related to Allergic Hypersensitivity Disease:


nausea and vomiting, abdominal pain, pruritus, tinnitus, syncope, stridor, snoring, sore throat, exanthema, coughing, vertigo/dizziness, equilibration disorder, signs and symptoms of ill-defined conditions, (non-specific) malaise and fatigue, injection site hypersensitivity, fever of unknown origin

MGI Mouse Phenotypes related to Allergic Hypersensitivity Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 CCL11 CCL17 CCL5 CCR3 EPX FCER2
2 digestive/alimentary MP:0005381 9.86 FCER2 IFNG IL10 IL13 IL4 IL5
3 immune system MP:0005387 9.83 CCL11 CCL17 CCL5 CCR3 EPX FCER2
4 respiratory system MP:0005388 9.17 CCL11 CCR3 IFNG IL10 IL13 IL4
Sources

Drugs & Therapeutics for Allergic Hypersensitivity Disease

About this section

PubMedHealth treatment related to Allergic Hypersensitivity Disease: 64

The best way to prevent allergic reactions is to avoid contact with the triggers (allergens). How well this works will mainly depend on the type of trigger. It’s often quite easy to avoid contact with things like certain foods or chemical substances. It’s almost impossible to avoid pollen, though. But pollen calendars and forecasts, for instance on the internet, can give you an idea of the pollen count in certain regions. People with dust mite allergies can somewhat lower their exposure to dust mites in their home by taking precautions such as using mite-proof bedding and removing "dust traps."The symptoms of many allergies can be treated with medication. Antihistamines and steroids are often used for this purpose. These medications are available in various forms, including tablets, nasal sprays and injections. They are mainly used in the treatment of allergic rhinitis (in the nose) and allergic conjunctivitis (in the eyes). Allergic reactions affecting the skin are also treated using steroid ointments or creams.A treatment known as allergen-specific immunotherapy (“desensitization”) can help reduce sensitivity to some allergens in the long term. Like with vaccines, this treatment approach involves exposing people to small amounts of the allergen. Here it is done at regular intervals by either injecting the allergen into your skin or placing it under your tongue. It takes about three to five years to complete allergen-specific immunotherapy. This approach is mainly used for the treatment of allergies to pollen (hay fever), dust mites and insect venom.There is currently no evidence that herbal or homeopathic products can help in the treatment of allergies. This is also true for acupuncture.

Drugs for Allergic Hypersensitivity Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1353)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ertapenem Approved, Investigational Phase 4,Not Applicable 153832-46-3 150610
2
Alcaftadine Approved Phase 4,Phase 3 147084-10-4 19371515
3
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-45-6 774
4
Naphazoline Approved, Investigational Phase 4,Phase 3 835-31-4 4436
5
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 299-42-3 9294
6
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90-82-4 7028
7
Pheniramine Approved Phase 4,Phase 3 86-21-5 4761
8
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7553-56-2 807
9
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90566-53-3 62924
10
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51333-22-3 5281004 63006
11
Omalizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 242138-07-4
12
Cyproheptadine Approved Phase 4,Phase 2 129-03-3 2913
13
Capsaicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 404-86-4 1548943
14
Azelastine Approved Phase 4,Phase 3,Not Applicable 58581-89-8 2267
15
Montelukast Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 158966-92-8 5281040
16
Nitric Oxide Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 10102-43-9 145068
17
Cetirizine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83881-51-0 2678
18
Caffeine Approved Phase 4 58-08-2 2519
19
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 85721-33-1 2764
20
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 443-48-1 4173
21
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 26787-78-0 33613
22
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53123-88-9 46835353 5284616 6436030
23
Resveratrol Approved, Experimental, Investigational Phase 4 501-36-0 445154
24
Indomethacin Approved, Investigational Phase 4,Early Phase 1,Not Applicable 53-86-1 3715
25
Sulbactam Approved Phase 4,Phase 3,Phase 2 68373-14-8
26
Piperacillin Approved Phase 4,Phase 3,Not Applicable 66258-76-2 43672
27
Midazolam Approved, Illicit Phase 4,Phase 1,Phase 2,Not Applicable 59467-70-8 4192
28
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 137-58-6 3676
29
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
30
Remifentanil Approved Phase 4 132875-61-7 60815
31
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1401-55-4
32
Chlorhexidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55-56-1 2713 9552079
33
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
34
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2921-57-5
35
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 83-43-2 6741
36
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032
37
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302-25-0
38
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-24-8 5755
39
Enalaprilat Approved Phase 4 76420-72-9 6917719
40
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
41
mometasone furoate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83919-23-7
42
Xylometazoline Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 526-36-3 5709
43
Acyclovir Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59277-89-3 2022
44
Tranexamic Acid Approved Phase 4 1197-18-8 5526
45
Alendronate Approved Phase 4,Phase 2 66376-36-1, 121268-17-5 2088
46
Povidone Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 9003-39-8
47
Clindamycin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 18323-44-9 29029
48
Teicoplanin Approved, Investigational Phase 4,Not Applicable 61036-62-2
49
Povidone-iodine Approved Phase 4,Phase 3,Not Applicable 25655-41-8
50
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 73590-58-6 4594

Interventional clinical trials:

(show top 50) (show all 5516)
# Name Status NCT ID Phase Drugs
1 Safety of Ertapenem in Beta-lactam Allergic Patients. Unknown status NCT01159379 Phase 4 ertapenem
2 Can we Help People With the Oral Allergy Syndrome Eat Fresh Fruit? Unknown status NCT01431859 Phase 4
3 Ocular Allergy Treatment Practical Impact Trial Unknown status NCT01808768 Phase 4 Alcaftadine
4 Growth, Safety and Tolerance of a Rice Protein Hydrolysate Formula in Infants With Cow's Milk Protein Allergy Unknown status NCT02405923 Phase 4
5 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
6 Evaluation of Efficacy of House Dust Mite Immunotherapy in Children With Bronchial Asthma Unknown status NCT00496574 Phase 4
7 Effect of Specific Immunotherapy to Dust Mites in Children With Asthma Unknown status NCT00496561 Phase 4
8 A Feasibility Study to Assess the Use of Gadolinium in Computed Tomography Unknown status NCT02163005 Phase 4 Gadolinium
9 Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS) Unknown status NCT00867737 Phase 4 Advair HFA MDI 115/21;Symbicort 160/4.5 pMDI
10 The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils Unknown status NCT00673218 Phase 4 Placebo;Xolair
11 Study With Rupatadine in Mosquito-Bite Allergic Adult Subjects Unknown status NCT00258141 Phase 4 Rupatadine;Placebo
12 Immunological Mechanisms of Oralair® in Patients With Seasonal Allergic Rhinitis Unknown status NCT02014623 Phase 4 Control
13 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
14 Hypervolemia in ESRD Patients in Zonguldak (Prospective Study) Unknown status NCT01468363 Phase 4
15 Comparative Study of Sinol and Sinol-M in Patients With Congestion Due to Allergic Rhinitis Unknown status NCT00825656 Phase 4 Sinol or Sinol-M nasal spray
16 AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR) Unknown status NCT02238353 Phase 4 azelastine + fluticasone;Placebo
17 Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo in Persistent Asthma. Unknown status NCT01939951 Phase 4
18 Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES) Unknown status NCT00406094 Phase 4 montelukast;placebo
19 Assessment of Sublingual Immunotherapy in Children Allergic to House Dust Mites Unknown status NCT01052610 Phase 4 sublingual house dust mites allergen extract;placebo in sublingual applicator
20 Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation in Children With Allergic Rhinitis Unknown status NCT00488176 Phase 4 montelukast;cetirizine;montelukast and cetirizine;placebo
21 Assessment of Utility of Exhaled Nitric Oxide Measurement for Treatment Monitoring in Children With Asthma Unknown status NCT00500253 Phase 4
22 Clinical Management of Childhood Intestinal Lymphoid Nodular Hyperplasia Unknown status NCT01789294 Phase 4 Mesalamine
23 Diverticulitis: Antibiotics or Close Observation? Unknown status NCT01111253 Phase 4 Amoxicillin-clavulanate
24 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment Unknown status NCT01880879 Phase 4
25 Oral Resveratrol to Prevent Post-ERCP Pancreatitis Unknown status NCT02947932 Phase 4 Resveratrol;Indomethacin
26 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
27 Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients Unknown status NCT02057523 Phase 4 Acthar
28 Safety Study of Enterovirus 71 Vaccine in Children Aged 6-35 Months Old Unknown status NCT02806531 Phase 4
29 Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection Unknown status NCT01897831 Phase 4 xin te mie
30 Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection Unknown status NCT01760109 Phase 4 Piperacillin Sodium and Sulbactam Sodium
31 the Research of Analgesia and Sedation Effect of Remifentanil on ICU Short Operation Unknown status NCT02635802 Phase 4 Remifentanil;Lidocaine;Remifentanil+Lidocaine;Midazolam
32 Study of Chlorhexidine as the Hub Antiseptic to Prevent Catheter Related Infections in Newborn Infants Unknown status NCT00516360 Phase 4
33 Rituximab in Recurrent IgA Nephropathy Unknown status NCT02571842 Phase 4 Intravenous Rituximab;ACEI/ARB and corticosteroids
34 Effect of Xolair on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4 Omalizumab;Placebo for Omalizumab;omalizumab
35 4"S" - Seasonal Symptoms Suppression Study Unknown status NCT02557269 Phase 4 Xylometazoline - intranasal application;Azelastine - intranasal application;Mometasone furoate - intranasal application;Hydroxyl-propyl-methyl cellulose powder - intranasal application;Bilastine 20 mg;Prednisolone 5 mg
36 Effect of HSV-2 Suppressive Therapy on Sexual Behavior Unknown status NCT00495716 Phase 4 acyclovir;acyclovir
37 Effectiveness of Intravenous Tranexamic Acid in Reducing Blood Loss During and After Cesarean Section Unknown status NCT02279186 Phase 4 Tranexamic Acid
38 Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment Unknown status NCT02371252 Phase 4 Generic alendronate
39 The Amputation Surgical Site Infection Trial (ASSIT) Unknown status NCT02018094 Phase 4 Co-amoxiclav;Iodine;Metronidazole;Chlorhexidine;Teicoplanin;Clindamycin
40 Effects of Montelukast in Asthmatic Children With and Without Food Allergy Completed NCT01618929 Phase 4 Montelukast
41 Safety of Oral Immunotherapy for Cow's Milk Allergy in School-aged Children Completed NCT01361347 Phase 4
42 Safety Trial of Atrovent® in Pediatric Patients With Rhinorrhea Associated With a Common Cold or Allergy Completed NCT02238210 Phase 4 Atrovent®
43 A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms Completed NCT00637884 Phase 4 Fexofenadine HCl
44 iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions Completed NCT02552537 Phase 4 Omeprazole;Placebo
45 Grass Pollen Subcutaneous Immunotherapy in Elderly Patients Completed NCT02440243 Phase 4 Purethal;Purethal -placebo
46 A Trial of Immunological Outcomes of Sublingual Immunotherapy for House Dust Mite (D. Pteronyssinus) Allergy Completed NCT00250263 Phase 4 (agent for immunotherapy) Staloral;Placebo
47 Efficacy of 2LALERG (Homeopathic Drug) in Allergic Rhinitis Related to Grass Pollen Completed NCT02690935 Phase 4 2LALERG;Placebo
48 Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens Completed NCT00557284 Phase 4 Montelukast;Placebo
49 Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis Completed NCT00534794 Phase 4 Elestat;Pataday
50 Effects of Sublingual Immunotherapy on Grasspollen Allergy Completed NCT00150514 Phase 4 Oralgen

Search NIH Clinical Center for Allergic Hypersensitivity Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: hypersensitivity

Sources

Genetic Tests for Allergic Hypersensitivity Disease

About this section
Sources

Anatomical Context for Allergic Hypersensitivity Disease

About this section

MalaCards organs/tissues related to Allergic Hypersensitivity Disease:

42
Testes, Skin, Lung, T Cells, Kidney, Liver, Bone
Sources

Publications for Allergic Hypersensitivity Disease

About this section

Articles related to Allergic Hypersensitivity Disease:

(show top 50) (show all 3085)
# Title Authors Year
1
Self-reported Sensory Hypersensitivity Moderates Association Between Tactile Psychophysical Performance and Autism-Related Traits in Neurotypical Adults. ( 31073751 )
2019
2
A comprehensive evaluation of emotional responsiveness in borderline personality disorder: a support for hypersensitivity hypothesis. ( 31110772 )
2019
3
Hypersensitivity Myocarditis and Necrotizing Coronary Vasculitis by Clomipramine Causing Steroid-Sensitive Cardiogenic Shock. ( 30744394 )
2019
4
Dampness and mold hypersensitivity syndrome and vaccination as risk factors for chronic fatigue syndrome. ( 30408578 )
2019
5
Blocking α2δ-1 Subunit Reduces Bladder Hypersensitivity and Inflammation in a Cystitis Mouse Model by Decreasing NF-kB Pathway Activation. ( 30863309 )
2019
6
A double-blinded, randomized, methylprednisolone-controlled study on the efficacy of oclacitinib in the management of pruritus in cats with nonflea nonfood-induced hypersensitivity dermatitis. ( 30656750 )
2019
7
Increased expression of brain-derived neurotrophic factor is correlated with visceral hypersensitivity in patients with diarrhea-predominant irritable bowel syndrome. ( 30670915 )
2019
8
Making Rash Decisions in Epilepsy: Evaluating Hypersensitivity Reactions to Anti-seizure Medications. ( 30955419 )
2019
9
New IgE immediate hypersensitivity reactions on reintroduction of food restricted for treatment of eosinophilic esophagitis. ( 30684739 )
2019
10
Associations Between Bone Mass in Women With Fibromyalgia and Widespread Pressure Pain Hypersensitivity, Tenderness, Perceived Pain Level, and Disability. ( 30917665 )
2019
11
Systemic growth hormone deficiency causes mechanical and thermal hypersensitivity during early postnatal development. ( 30815617 )
2019
12
Eculizumab hypersensitivity and desensitization in a toddler with atypical hemolytic uremic syndrome. ( 30946976 )
2019
13
MiR-187-3p mimic alleviates ischemia-reperfusion-induced pain hypersensitivity through inhibiting spinal P2X7R and subsequent mature IL-1β release in mice. ( 31100367 )
2019
14
Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06. ( 30632847 )
2019
15
A case of Nodal Marginal Zone Lymphoma with Hypersensitivity to mosquito bites as initial symptom. ( 31095761 )
2019
16
Imported Fire Ant Hypersensitivity and Mastocytosis: A Case Series of Successful Venom Immunotherapy. ( 30831255 )
2019
17
Report of a rare case of severe allergic reaction due to nasal myiasis and a brief review of the literature in Turkey. ( 31007925 )
2019
18
Cough hypersensitivity in patients with obstructive sleep apnea hypopnea syndrome. ( 29453637 )
2019
19
Azathioprine hypersensitivity syndrome in anti-myeloperoxidase anti-neutrophil cytoplasmic antibody-associated vasculitis. ( 30746133 )
2019
20
Dentinal Hypersensitivity Treatment Using Diode Laser 980 nm: In Vivo Study. ( 30634421 )
2019
21
Influence of Visual and Vestibular Hypersensitivity on Derealization and Depersonalization in Chronic Dizziness. ( 30814972 )
2019
22
Hypersensitivity pneumonitis: A new strategy for serodiagnosis and environmental surveys. ( 30961934 )
2019
23
Prognostic value of hypersensitivity reactions on epidural steroid injection outcomes: a phenotypic signature? A prospective cohort study. ( 30962251 )
2019
24
An EAACI position paper on the investigation of perioperative immediate hypersensitivity reactions. ( 30964555 )
2019
25
An Exploratory Randomised Study to Evaluate the Efficacy of an Experimental Occlusion-based Dentifrice in the Relief of Dentin Hypersensitivity. ( 30968066 )
2019
26
Forced Oscillation Technique and Small Airway Involvement in Chronic Hypersensitivity Pneumonitis. ( 30975515 )
2019
27
Prevalence of food hypersensitivity in relation to IgE sensitisation to common food allergens among the general adult population in West Sweden. ( 30976385 )
2019
28
Silencing of PD-L2/B7-DC by Topical Application of Small Interfering RNA Inhibits Elicitation of Contact Hypersensitivity. ( 30978356 )
2019
29
Decreased miR-325-5p Contributes to Visceral Hypersensitivity Through Post-transcriptional Upregulation of CCL2 in Rat Dorsal Root Ganglia. ( 30980241 )
2019
30
Radiocontrast Media Hypersensitivity: Skin Testing Differentiates Allergy From Nonallergic Reactions and Identifies a Safe Alternative as Proven by Intravenous Provocation. ( 30980898 )
2019
31
Pain Intensity, Pressure Pain Hypersensitivity, Central Sensitization, and Pain Catastrophizing Related to Vascular Alterations in Raynaud's Phenomenon: A Preliminary Case-Control Study. ( 30986311 )
2019
32
The efficacy and safety of Sipjeondaebo-tang in Korean patients with cold hypersensitivity in the hands and feet: a protocol for a pilot, randomized, double-blind, placebo-controlled, parallel-group clinical trial. ( 30987667 )
2019
33
Ovarian Hormone-dependent and Spinal ERK Activation-regulated Nociceptive Hypersensitivity in Female Rats with Acid Injection-induced Chronic Widespread Muscle Pain. ( 30816240 )
2019
34
Oral challenge without skin testing in children with suspected non-severe betalactam hypersensitivity. ( 30817036 )
2019
35
Dentine hypersensitivity-like tooth pain associated with the use of high-dose steroid therapy. ( 30820092 )
2019
36
Prediction of itching diagnostic marker through RNA sequencing of contact hypersensitivity and skin scratching stimulation mice models. ( 30820159 )
2019
37
Immediate hypersensitivity to polyethylene glycols in unrelated products: when standardization in the nomenclature of the components of drugs, cosmetics, and food becomes necessary. ( 30820197 )
2019
38
Drug-induced tubulointerstitial nephritis: hypersensitivity and necroinflammatory pathways. ( 30820701 )
2019
39
Prevalence and predictive factors of dentin hypersensitivity in Brazilian adolescents. ( 30825378 )
2019
40
Material Hypersensitivity and Alloplastic Temporomandibular Joint Replacement. ( 30825437 )
2019
41
Severe life-threatening hypersensitivity reaction to polidocanol in a case of recurrent aneurysmal bone cyst. ( 30828217 )
2019
42
Carotid sinus hypersensitivity. ( 30829401 )
2019
43
Mechanisms of hypersensitivity reactions induced by drugs. ( 30830061 )
2019
44
Hypersensitivity reactions to food and drug additives: problem or myth? ( 30830065 )
2019
45
Pediatric drug hypersensitivity: which diagnostic tests? ( 30830067 )
2019
46
Erratum to "An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity". ( 30838223 )
2019
47
NUDT15 Polymorphism identified in an Azathioprine Hypersensitivity Syndrome Presenting as Erythema Nodosum and Hepatotoxicity. ( 30843183 )
2019
48
Immune pathomechanism and classification of drug hypersensitivity. ( 30843233 )
2019
49
Dietary coconut oil ameliorates skin contact hypersensitivity through mead acid production in mice. ( 30843234 )
2019
50
Efficacy of a 3% potassium nitrate mouthrinse for the relief of dentinal hypersensitivity: An 8-week randomized controlled study. ( 30803493 )
2019
Sources

Variations for Allergic Hypersensitivity Disease

About this section

ClinVar genetic disease variations for Allergic Hypersensitivity Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 46;XX;t(4;14)(p15.2;q13)dn Translocation Likely pathogenic
2 SLC9A6 NM_001042537.1(SLC9A6): c.1346C> A (p.Ala449Glu) single nucleotide variant Uncertain significance rs1556619324 GRCh37 Chromosome X, 135098913: 135098913
3 SLC9A6 NM_001042537.1(SLC9A6): c.1346C> A (p.Ala449Glu) single nucleotide variant Uncertain significance rs1556619324 GRCh38 Chromosome X, 136016754: 136016754
4 GFOD1; MCUR1; NOL7; PHACTR1; RANBP9; RNF182; SIRT5; TBC1D7 GRCh37/hg19 6p24.1-23(chr6: 12536624-13968949) copy number gain Uncertain significance GRCh37 Chromosome 6, 12536624: 13968949
Sources

Expression for Allergic Hypersensitivity Disease

About this section
Search GEO for disease gene expression data for Allergic Hypersensitivity Disease.
Sources

Pathways for Allergic Hypersensitivity Disease

About this section

Pathways related to Allergic Hypersensitivity Disease according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 14.03 CCL11 CCL5 EPX FCER2 IFNG IGHE
2
ERK Signaling 65
Show member pathways
 13.86 CCL11 CCL17 CCL5 CCR3 HRH4 IL10
3
PEDF Induced Signaling 65
Show member pathways
 13.71 CCL11 CCL17 CCL5 CCR3 FCER2 HRH4
4
TGF-Beta Pathway 65
Show member pathways
 13.55 CCL11 CCL17 CCL5 IFNG IL10 IL13
5
Akt Signaling 65
Show member pathways
 13.46 CCL11 CCL17 CCL5 CCR3 HRH4 IL10
6
Cytokine Signaling in Immune system 67
Show member pathways
 13.42 CCL11 CCL5 FCER2 IFNG IGHE IL10
7
PAK Pathway 65
Show member pathways
 13.32 CCL11 CCL17 CCL5 CCR3 HRH4 IL10
8
Allograft rejection 38 1
Show member pathways
 12.94 CCL11 EPX IFNG IL10 IL13 IL4
9
CCR5 Pathway in Macrophages 65
Show member pathways
 12.82 CCL11 CCL17 CCL5 CCR3 HRH4
10
Pathways in cancer 38
12.79 IFNG IL13 IL4 IL5 KITLG
11
NF-kappaB Signaling 4
12.6 CCL5 IFNG IL10 IL4 KITLG TPT1
12
Th17 cell differentiation 38
Show member pathways
 12.59 IFNG IL10 IL13 IL4 IL5
13
T cell receptor signaling pathway 38
Show member pathways
 12.58 IFNG IL10 IL4 IL5 IL9
14
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.45 IFNG IL10 IL13 IL4 IL5 IL9
15
Development IG